Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | USP7 | Q93009 | 2/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7219748 | 0.84 | PDCD1 (0.38) | CYP2A6RAF1CYP11B1CYP11B2PDCD1 | |
| SCHEMBL2560682 | 0.83 | ADORA2A (0.43) | RAF1CYP11B1CYP11B2HRH3GRIN1 | |
| SCHEMBL7220029 | 0.81 | TSHR (0.44) | RAF1PDCD1CD274GRIN1GRIN2B | |
| SCHEMBL16619272 | 0.80 | LOXL2 (0.52) | RAF1PDCD1CD274HRH3 | |
| SCHEMBL18761092 | 0.80 | PDCD1 (0.41) | RAF1USP7PDCD1CD274HRH3 | |
| SCHEMBL1413419 | 0.79 | GRIN2B (0.40) | RAF1CYP11B1CYP11B2HRH3GRIN1 | |
| SCHEMBL19911768 | 0.79 | CYP11B2 (0.47) | RAF1CYP11B1CYP11B2PDCD1CD274 | |
| SCHEMBL1413347 | 0.79 | LOXL2 (0.48) | RAF1CYP11B1CYP11B2HRH3GRIN1 | |
| SCHEMBL7673123 | 0.79 | CYP11B1 (0.38) | RAF1CYP11B1CYP11B2PDCD1CD274 | |
| SCHEMBL1413439 | 0.79 | CYP11B1 (0.47) | CYP2A6RAF1USP7CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230045960-A1 | SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-16 | — | — | US | disclosed |
| US-20220220106-A1 | QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2022-07-14 | — | — | US | disclosed |
| US-11352363-B1 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20220162216-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
| US-20210379113-A1 | METHODS FOR HEMATOPOIETIC STEM AND PROGENITOR CELL TRANSPLANT THERAPY | EDIGENE BIOTECHNOLOGY, INC. (CN) | 2021-12-09 | — | — | US | disclosed |
| US-20210317103-A1 | ASK1 INHIBITING AGENTS | BIOGEN MA INC. | 2021-10-14 | — | — | US | disclosed |
| US-20210299115-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2021-09-30 | — | — | US | disclosed |
| US-11026937-B2 | Heteroaryl inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| WO-2021063404-A1 | COMPOUND AS SMALL MOLECULE INHIBITOR PD-1/PD-L1 AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2021-04-08 | — | — | WO | disclosed |
| US-20100022522-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | Incyte Corporationn, a Delaware corporation | 2010-01-28 | — | — | US | disclosed |
| US-20090258864-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090069284-A1 | Substituted 3-alkyl and 3-alkenyl azetidine derivatives | MERCK SHARP & DOHME CORP. | 2009-03-12 | — | — | US | disclosed |
| US-7485732-B2 | Substituted 3-alkyl and 3-alkenyl azetidine derivatives | MERCK & CO., INC. (US) | 2009-02-03 | — | — | US | disclosed |
| EP-1490371-B1 | THIOPHENE-BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL MYERS SQUIBB CO (US) | 2007-08-15 | — | — | EP | disclosed |
| US-6603007-B1 | Intermediates in the fields of pharmaceuticals, agrichemicals, ligands, silver halide photosensitive materials, liquid crystals, surfactants, electrophotography and organic electroluminescence | SANKIO CHEMICAL CO., LTD. (JP) | 2003-08-05 | — | — | US | disclosed |
| EP-1231207-A1 | NOVEL BIPYRIDYL DERIVATIVES | Sankio Chemical Co., Ltd. (JP) | 2002-08-14 | — | — | EP | disclosed |
| EP-0634400-B1 | PYRIDINECARBOXIMIDAMIDE COMPOUND AND USE THEREOF | KIRIN BREWERY (JP) | 1997-04-02 | — | — | EP | disclosed |
| US-5508293-A | TREATING HYPERTENSION, ANGINA PECTORIS | KIRIN BEER KABUSHIKI KAISHA (JP) | 1996-04-16 | — | — | US | disclosed |
| EP-0634400-A1 | PYRIDINECARBOXIMIDAMIDE COMPOUND AND USE THEREOF | KIRIN BEER KABUSHIKI KAISHA (JP) | 1995-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317103-A1 | ASK1 INHIBITING AGENTS | MAP3K1, MAP3K6, MAP3K10 | CYP2A6 3429/4885RAF1 49/4885USP7 1697/4885 |
| US-20230045960-A1 | SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | CYP2A6 1233/4885RAF1 2989/4885USP7 3788/4885 |
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | CYP46A1, CYP26A1, CYP4A22 | CYP2A6 10/4885RAF1 2703/4885USP7 2644/4885 |
| US-20210379113-A1 | METHODS FOR HEMATOPOIETIC STEM AND PROGENITOR CELL TRANSPLANT THERAPY | HCLS1, MPST, THPO | CYP2A6 3477/4885RAF1 2281/4885USP7 3536/4885 |
| US-20210299115-A1 | HETEROARYL INHIBITORS OF PAD4 | PADI4, PADI1, PADI6 | CYP2A6 2335/4885RAF1 2688/4885USP7 822/4885 |
| US-20100022522-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | CYP2A6 2442/4885RAF1 524/4885USP7 2467/4885 |
| US-20090069284-A1 | Substituted 3-alkyl and 3-alkenyl azetidine derivatives | CNR1, CNR2, MAG | CYP2A6 598/4885RAF1 1869/4885USP7 2529/4885 |
| US-20220162216-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, REN | CYP2A6 686/4885RAF1 2851/4885USP7 4040/4885 |
| US-11026937-B2 | Heteroaryl inhibitors of PAD4 | PADI4, PADI1, PADI6 | CYP2A6 2335/4885RAF1 2688/4885USP7 822/4885 |
| US-20220220106-A1 | QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | MTOR, RICTOR, EIF4E | CYP2A6 2037/4885RAF1 397/4885USP7 3236/4885 |
| US-20090258864-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | JAK2, JAK1, JAK3 | CYP2A6 2529/4885RAF1 274/4885USP7 3855/4885 |
| US-11352363-B1 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, REN | CYP2A6 524/4885RAF1 2900/4885USP7 4179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.